Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: A Phase 2 Study of SHR-1210 (PD-1 Antibody) in Combination With Apatinib or FOLFOX4 Regimen in Subjects With Advanced Primary Liver Cancer（PLC）
Brief Summary:
This an open-label，Non-Randominzed Phase 2 study to evaluate the Safety and Tolerability of SHR-1210 in combination with Apatinib or FOLFOX4 regimen in subjects with Advanced PLC.
Participants with advanced PLC who failed or intolerable to prior systemic therapy will be treated with SHR-1210 plus Apatinib; Participants with advanced PLC who have never received prior systemic therapy will be treated with SHR-1210 plus FOLFOX4 regimen.